|
23 Sep 2020 |
FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma
|
|
23 Sep 2020 |
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
|
|
23 Sep 2020 |
Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
|
|
23 Sep 2020 |
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn's disease
|
|
23 Sep 2020 |
TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis
|
|
23 Sep 2020 |
Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes
|
|
22 Sep 2020 |
OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib
|
|
22 Sep 2020 |
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020
|
|
21 Sep 2020 |
Discovery of a druggable pocket in the SARS-CoV-2 Spike protein could stop virus in its tracks
|
|
21 Sep 2020 |
Sotorasib (AMG 510) Shows Promising Results in Some Patients With Solid Tumors, Suggests a Study With City of Hope as a Co-Lead Author
|
|
21 Sep 2020 |
Algiax Pharmaceuticals Announces First Patient Enrolled in Phase IIa Multi-center Proof-of-Concept Study Evaluating AP-325 in Chronic Neuropathic Pain
|
|
21 Sep 2020 |
Lynparza reduced the risk of death by 31% in BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in PROfound Phase III trial
|
|
21 Sep 2020 |
Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer
|
|
21 Sep 2020 |
Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
|
|
21 Sep 2020 |
Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer
|
|
20 Sep 2020 |
Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
|
|
20 Sep 2020 |
Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
|
|
20 Sep 2020 |
Orfadin® (nitisinone) receives positive opinion from CHMP for treatment of AKU
|
|
20 Sep 2020 |
Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors
|
|
20 Sep 2020 |
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
|
|
20 Sep 2020 |
Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020 Virtual Annual Congress
|
|
20 Sep 2020 |
LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo
|
|
20 Sep 2020 |
TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
|
|
18 Sep 2020 |
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease
|
|
18 Sep 2020 |
eXIthera Announces Publication of EP-7041 Data Demonstrating Safe Antithrombotic Activity in ECMO
|
